Bioton (FRA:7U5) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7U5 Bioton SA FRA:7U5
60 GF Score
Price €0.86
GF Value €1.06
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioton Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

FRA:7U5
60GF Score
Bioton SA FRA:7U5
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioton (FRA:7U5) Overvalued in 2026?

Based on GuruFocus' analysis, Bioton stock appears to be undervalued. The current stock price of €0.86 is trading 18.7% below its estimated GF Value™ of €1.06. GuruFocus considers Bioton to be Modestly Undervalued.

Key valuation signals for FRA:7U5:

  • Total Noninterest Expense:
  • GF Value™: €1.06 vs. price of €0.86 (18.7% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the FRA:7U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioton Business Description

Other Exchanges BIO:Poland
Address Ul. Starościńska 5, Warszawa, POL, 02-516
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
60GF Score

Get the complete analysis for FRA:7U5

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€1.06
GF Value